Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Gene therapy as a future treatment for hemophilia

Wolfgang Miesbach • 25 May 2021
EHA 2021
Hemophilia Non-Malignant

Wolfgang Miesbach, MD, PhD, University Hospital Frankfurt, Frankfurt, Germany, discusses why he thinks gene therapy is the most promising future treatment for hemophilia. Prof. Miesbach reports that single administrations of gene therapies have the potential to enable patients to cease prophylaxis and “lead a normal life”. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Wolfgang Miesbach, MD, PhD, discloses links to Bayer, Biomarin, Biotest, CSL Behring, Chugai, Freeline, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Takeda/Shire, uniQure.

More from Wolfgang Miesbach

5:18
HOPE-B: etranacogene dezaparvovec in adult hemophilia B
Wolfgang Miesbach • 25 May 2021
1:11
Current treatment options for hemophilia A
Wolfgang Miesbach • 25 May 2021

Related Videos

2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
1:23
Developing a PRO collection tool for patients with SCD: key themes which are important to patients
Nirmish Shah • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals